Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS other · 2025-12-16Clinical Trial Update: Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)
This update notes that the pre-approval access single-patient program for Teclistamab (JNJ-64007957) in multiple myeloma is no longer availa…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
This clinical trial update covers a Phase 2 study of daratumumab in newly diagnosed multiple myeloma. The study is currently active but not …
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment [Phase 2]
Phase 2 multicenter, non-blinded trial evaluating home self-administration of chemotherapy for multiple myeloma; currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
A clinical trial is updating practices around anonymizing data from pseudonymized databases collected in prior multiple myeloma trials.
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse [NA]
A terminated Phase 1-2 study evaluating total bone marrow irradiation with helicoidal tomotherapy for first relapse multiple myeloma has res…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: FT576 in Subjects With Multiple Myeloma [Phase 1]
This document is a status update for a Phase 1 clinical trial of FT576 in multiple myeloma. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma [Phase 3]
Phase 3 trial evaluating isatuximab in combination with lenalidomide and dexamethasone for high-risk smoldering multiple myeloma; currently …
-
CLINICAL_TRIALS other · 2025-12-12Clinical Trial Update: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Expanded Access Protocol update for idecabtagene vicleucel in multiple myeloma patients that are nonconforming for commercial release; provi…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating a combination of elotuzumab, iberdomide, and dexamethasone after idecabtagene vicleucel (ide-cel) i…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors [Phase 1]
Phase 1 study assessing a subcutaneous formulation of TQB2934 for injection in subjects with malignant plasma cell tumors, including multipl…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Plan Development for Giving Teclistamab in the Outpatient Setting [Phase 4]
Plan development for delivering teclistamab to patients with relapsed/refractory multiple myeloma in the outpatient setting as part of a Pha…
-
EMA approval · 2025-12-09EMA Authorised: Abecma (idecabtagene vicleucel) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Abecma (idecabtagene vicleucel) for treatment of multiple myeloma in adults. It is designated as an…
-
CLINICAL_TRIALS approval · 2025-12-09Clinical Trial Update: Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
The update reports that Janssen's talquetamab for relapsed or refractory multiple myeloma has been approved for marketing under a pre-approv…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
A registry study to evaluate cancer and aging resilience in older adults with hematologic malignancies, including multiple myeloma, amyloido…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) [Phase 1]
Update on the Phase 1 study of HPN217 (MK-4002-001) for relapsed/refractory multiple myeloma, indicating the trial remains active but not re…
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]
A Phase 2 clinical trial is evaluating daratumumab after stem cell transplant in patients with multiple myeloma. The study is currently acti…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma [Phase 3]
This is a Phase 3 clinical trial comparing Selinexor, Pomalidomide, and Dexamethasone (SPd) against Elotuzumab, Pomalidomide, and Dexamethas…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy [Phase 1]
A Phase 1 trial evaluating the combination of duvelisib with BMS-986345 in lymphoid malignancies, including non-Hodgkin lymphoma and Hodgkin…
-
CLINICAL_TRIALS withdrawal · 2025-12-04Clinical Trial Update: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function [Phase 1]
A Phase 1 study evaluating belantamab mafodotin in multiple myeloma patients with varying hepatic function has been withdrawn.
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating LBL-034 in patients with relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients [Phase 1]
This is a Phase I study evaluating conditioning with bendamustine and melphalan followed by autologous stem cell transplantation for elderly…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
A completed clinical trial update examining patient experiences and treatment preferences for multiple myeloma.
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma [Phase 2]
A Phase 2 trial evaluating elranatamab in patients with clinically high-risk relapsed multiple myeloma after cilta-cel; the study is current…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy [Phase 2]
Phase II trials are evaluating letermovir prophylaxis in relapsed/refractory multiple myeloma patients receiving elranatamab, with recruitme…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA [Phase 4]
A Phase 4 clinical trial update from the University of Turin comparing two standard treatments for multiple myeloma in patients ineligible f…